A Novel Point Mutation of the Splicing Donor Site in the Intron 2 of the Plasmin Inhibitor Gene

Haruhiko Yoshinaga; Shinsaku Hirosawa; Dong Hui Chung; Nobuyuki Miyasaka; Nobuo Aoki; Remi Favier

doi:10.1055/s-0037-1614012

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2000; 84(02): 307-311
DOI: 10.1055/s-0037-1614012

Review Article

Schattauer GmbH

A Novel Point Mutation of the Splicing Donor Site in the Intron 2 of the Plasmin Inhibitor Gene

Haruhiko Yoshinaga

¹From the First Department of Internal Medicine, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan

,

Shinsaku Hirosawa

¹From the First Department of Internal Medicine, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan

,

Dong Hui Chung

¹From the First Department of Internal Medicine, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan

,

Nobuyuki Miyasaka

¹From the First Department of Internal Medicine, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan

,

Nobuo Aoki

¹From the First Department of Internal Medicine, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan

,

Remi Favier

²Laboratory of Hematology and Hemostasis, Hospital Armand Trousseau, Paris, France

› Author Affiliations

Abstract

Summary

Plasmin inhibitor (PI) is a major physiological inhibitor of plasminmediated fibrinolysis; hence, its deficiency results in a severe haemorrhagic diathesis. We analyzed the PI gene of a French boy apparently homozygous for PI deficiency and his heterozygous parents. Both alleles of the homozygous patient had a novel G to A transition at the consensus splicing donor site in the intron 2 of the PI gene. In an expression assay using the heterologous cells transfected with the mutant PI expression vector, 3 types of aberrant transcripts using a cryptic splicing donor site within the intron 2 were detected. All of these mRNAs had a stop codon upstream of the cryptic splicing site and encode only 25 amino acids, comprising the first 21 amino acids of the signal peptide (27 amino acids) plus 4 new amino acids. This mutant was designated as PI-Paris-Trousseau.

Keywords

Plasmin inhibitor - mutation - fibrinolysis - splicing donor site

Full Text

References

References
1 Moroi M, Aoki N. Isolation and characterization of α₂-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activatorinduced clot lysis. J Biol Chem 1976; 251: 5956-65.
2 Aoki N, Moroi M, Matsuda M, Tachiya K. The behavior of α₂-plasmin inhibitor in fibrinolytic states. J Clin Invest 1977; 60: 361-9.
3 Aoki N, Harpel PC. Inhibitors of the fibrinolytic enzyme system. Semin Thromb Hemost 1984; 10: 24-41.
4 Wiman B, Collen D. On the kinetics of the reaction between human antiplasmin and plasmin. Eur J Biochem 1978; 84: 573-8.
5 Aoki N, Moroi M, Tachiya K. Effects of α₂-plasmin inhibitor on fibrin clot lysis. Its comparison with α₂-macroglobulin. Thromb Haemost 1978; 39: 22-31.
6 Sakata Y, Aoki N. Cross-linking of α₂-plasmin inhibitor to fibrin by fibrinstabilizing factor. J Clin Invest 1980; 65: 290-7.
7 Sakata Y, Aoki N. Significance of cross-linking of α₂-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis. J Clin Invest 1982; 69: 536-42.
8 Jansen JW, Haverkate F, Koopman J, Nieuwenhuis HK, Kluft C, Boschman TA. Influence of factor XIIIa activity on human whole blood clot lysis in vitro. Thromb Haemost 1987; 57: 171-5.
9 Bangert K, Johnsen AH, Christensen U, Thorsen S. Different N-terminal forms of α₂-plasmin inhibitor in human plasma. Biochem J 1993; 291: 623-5.
10 Koyama T, Koike Y, Toyota S, Miyagi F, Suzuki N, Aoki N. Different NH₂-terminal form with 12 additional residues of α₂-plasmin inhibitor from human plasma and culture media of Hep G2 cells. Biochem Biophys Res Commun 1994; 200: 417-22.
11 Sumi Y, Ichikawa Y, Nakamura Y, Miura O, Aoki N. Expression and characterization of the pro α₂-plasmin inhibitor. J Biochem 1989; 106: 703-7.
12 Hirosawa S, Nakamura Y, Miura O, Sumi Y, Aoki N. Organization of the human α₂-plasmin inhibitor gene. Proc Natl Acad Sci USA 1988; 85: 6836-40.
13 Kato A, Hirosawa S, Toyota S, Nakamura Y, Nishi H, Kimura A, Sasazuki T, Aoki N. Localization of the human α₂-plasmin inhibitor gene (PLI) to 17p13. Cytogenet Cell Genet 1993; 62: 190-1.
14 Aoki N, Saito H, Kamiya T, Koie K, Sakata Y, Kobakura M. Congenital deficiency of α₂-plasmin inhibitor associated with severe hemorrhagic tendency. J Clin Invest 1979; 63: 877-84.
15 Aoki N, Sakata Y, Matsuda M, Tateno K. Fibrinolytic states in a patient with congenital deficiency of α₂-plasmin inhibitor. Blood 1980; 55: 483-8.
16 Saito H. α₂-plasmin inhibitor and its deficiency states. J Lab Clin Med 1988; 112: 671-8.
17 Aoki N. Hemostasis associated with abnormalities of fibrinolysis. Blood Rev 1989; 03: 11-7.
18 Kluft C, Nieuwenhuis HK, Rijken DC, Groeneveld E, Hijngaards G, van Berke W, Dooijewaards G, Sixma JJ. α₂-Antiplasmin Enschede: dysfunctional α₂-antiplasmin molecule associated with an autosomal recessive hemorrhagic disorder. J Clin Invest 1987; 80: 1391-400.
19 Holmes WE, Lijnen HR, Nelles L, Kluft C, Nieuwenhuis HK, Rijken DC, Collen D. α₂-antiplasmin Enschede: alanine insertion and abolition of plasmin inhibitory activity. Science 1987; 238: 209-11.
20 Miura O, Hirosawa S, Kato A, Aoki N. Molecular basis for congenital deficiency of α₂-plasmin inhibitor. A frameshift mutation leading to elongation of the deduced amino acid sequence. J Clin Invest 1989; 83: 1598-604.
21 Miura O, Sugahara Y, Aoki N. Hereditary α₂-plasmin inhibitor deficiency caused by a transportdeficient mutation (α₂-PI-Okinawa). Deletion of Glu137 by a trinucleotide deletion blocks intracellular transport. J Biol Chem 1989; 264: 18213-9.
22 Miura O, Aoki N. Impaired secretion of mutant α₂-plasmin inhibitor (α₂PINara) from COS-7 and HepG2 cells: molecular and cellular basis for hereditary deficiency of α₂-plasmin inhibitor. Blood 1990; 75: 1092-6.
23 Toyota S, Hirosawa S, Aoki N. Secretion of α₂-plasmin inhibitor is impaired by amino acid deletion in a small region of the molecule. J Biochem (Tokyo) 1994; 115: 293-7.
24 Paqueron X, Favier R, Richard P, Maillet J, Murat I. Severe postadenoidectomy bleeding revealing congenital α₂ antiplasmin deficiency in a child. Anesth Analg 1997; 84: 1147-9.
25 Devaussuzenet VMP, Ducou-le-Pointe HA, Doco AM, Mary PM, Montagne JR, Favier R. A case of intramedullary haematoma associated with congenital α₂-plasmin inhibitor deficiency. Pediatr Radiol 1998; 28: 978-80.
26 Giannelli F, Green PM, Sommer SS, Poon M, Ludwig M, Schwaab R, Reitsma PH, Goossens M, Yoshioka A, Figueiredo MS, Brownlee GG. Haemophilia B: database of point mutations and short additions and deletions – eighth edition. Nucleic Acids Res 1998; 26: 265-8.
27 Reitsma PH, Poort SR, Bernardi F, Gandrille S, Long GL, Sala N, Cooper DN. Protein C deficiency: a database of mutations. For the Protein C & S Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1993; 69: 77-84.
28 Krawczak M, Reiss J, Cooper DN. The mutational spectrum of single basepair substitutions in mRNA splice junctions of human genes: causes and consequences. Hum Genet 1992; 90: 41-54.
29 Treisman R, Proudfoot NJ, Shander M, Maniatis T. A single-base change at a splice site in a β₀-thalassemic gene causes abnormal RNA splicing. Cell 1982; 29: 903-11.
30 Berg LP, Grundy CB, Thomas F, Millar DS, Green PJ, Slomski R, Reiss J, Kakkar W, Cooper DN. De novo splice site mutation in the antithrombin III (AT3) gene causing recurrent venous thrombosis: demonstration of exon skipping by ectopic transcript analysis. Genomics 1992; 13: 1359-61.
31 Shapiro MB, Senapathy P. RNA splice junctions of different classes of eukaryotes: sequence statistics and functional implications in gene expression. Nucleic Acids Res 1987; 15: 7155-74.
32 Robberson BL, Cote GJ, Berget SM. Exon definition may facilitate splice site selection in RNAs with multiple exons. Mol Cell Biol 1990; 10: 84-94.
33 Chung DH, Ohashi K, Watanabe M, Miyasaka N, Hirosawa S. Mannose trimming targets mutant α₂-plasmin inhibitor for degradation by the proteasome. J Biol Chem 2000; 275: 4981-7.